Related Experiment Video
Updated: Jul 29, 2025
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Role of miR-182 in cardiovascular and cerebrovascular diseases
Gaiqin Pei1,2, Li Chen3, Yang Wang1,2
1Department of Rehabilitation Medicine and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Insights
MicroRNAs, specifically miR-182, play a key role in various heart conditions like atherosclerosis and heart failure. Research explores miR-182 therapeutics for improved cardiovascular disease treatment.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biochemistry
Background:
- Cardiovascular and cerebrovascular diseases remain leading causes of mortality globally.
- Despite advances, atherothrombotic complications pose significant health challenges.
- MicroRNAs (miRNAs) are crucial regulators of gene expression with therapeutic potential.
Purpose of the Study:
- To elucidate the multifaceted role of miR-182 in cardiovascular pathophysiology.
- To review the therapeutic applications of miR-182 in clinical development.
- To identify challenges hindering miR-182's clinical translation for cardiac diseases.
Main Methods:
- Literature review and synthesis of existing research on miR-182.
- Analysis of miR-182's involvement in myocardial processes (proliferation, apoptosis, etc.).
- Examination of miR-182's role in various cardiac conditions (atherosclerosis, heart failure, etc.).
Main Results:
- miR-182 is implicated in regulating key cellular events relevant to cardiovascular diseases.
- It influences myocardial proliferation, migration, hypoxia, ischemia, apoptosis, and hypertrophy.
- miR-182's dysregulation is observed across conditions including atherosclerosis, myocardial infarction, and heart failure.
Conclusions:
- miR-182 is a significant regulator in diverse cardiac pathologies.
- Current miR-182 therapeutics show promise but face clinical development hurdles.
- Targeting miR-182 offers a potential novel strategy for cardiovascular disease treatment.
Abstract:
The treatment of cardiovascular and cerebrovascular diseases have undergone major advances in recent decades, allowing for a more effective prevention of cardiovascular and cerebrovascular events. However, cardiac and cerebral atherothrombotic complications still account for substantial morbidity and mortality worldwide. Novel therapeutic strategies are critical to improve patient outcomes following cardiovascular diseases. miRNAs are small non-coding RNAs, that regulate gene expression. Here, we discuss the role of miR-182 in regulating myocardial proliferation, migration, hypoxia, ischemia, apoptosis and hypertrophy in atherosclerosis, CAD, MI, I/R injury, organ transplant, cardiac hypertrophy, hypertension, heart failure, congenital heart disease and cardiotoxicity. Besides, we also summarize the current progress of miR-182 therapeutics in clinical development and discuss challenges that will need to be overcome to enter the clinic for patients with cardiac disease.
Related Concept Videos
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:26Coronary Artery Disease II: Pathophysiology
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:29Hypertension II: Pathophysiology
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:22MicroRNAs